This article is more than 5 years old. Information may no longer be current.
EV71 vaccine booster dose may improve immunogenicity
Click Here to Manage Email Alerts
A booster dose of the enterovirus 71 vaccine a year after original vaccination could help improve immunogenicity, according to recent study findings published in the Journal of Infectious Diseases.
Zhu Fengcai, MSc, of the Jiangsu Provincial CDC, and colleagues evaluated 707 children aged 6 to 35 months who received at least one dose of priming enterovirus 71 (EV71) vaccine to determine whether a booster dose would improve immunogenicity. Patients were grouped according to vaccine formulations vs. placebo, 160 U, 320 U, 640 U with adjuvant, and 640 U without adjuvant.
Among all vaccine groups, geometric mean titers (GMTs) were >138.2; however, the 320 U and 640 U with adjuvant groups were higher than the 640 U without adjuvant group.
Strong immune responses were found after 28 days in each vaccine group compared with the placebo group, which showed nearly no activation of immune response. The 640 U with adjuvant group had the highest GMTs (4,410.7), followed by the 320 U group (3,352.5). The lowest GMTs were found among the 160 U group (2,352.6) and the 640 U with adjuvant group (2,214.8).
Patients who received the 640 U with adjuvant formulation had the highest seroconversion rate (92.1%), followed by 320 U, 160 U, and the 640 U without adjuvant.
At least one adverse reaction was reported among 28.5% of patients.
“Despite the high pre-vaccination EV71 antibody more or less has compromised the reasonability of this booster immunization at 1 year after the priming EV71 vaccinations, a booster dose of EV71 vaccine in any formulation was proved to have the ability to elicit remarkable anamnestic response, which may result in a long duration of antibody persistence and protect children from EV71-associated disease,” the researchers wrote. “In view of the potential for booster dose injection in future, especially after the approval of EV71 vaccine for market, continuous observations should be performed on the protection of EV71 vaccines and the incidence of EV71 associated-disease in vaccinated children.”
Disclosure: The study was funded in part by Beijing Vigoo Biological Co., Ltd. and China 12-5 National Major Infectious Disease Programs. Four researchers report financial ties with the National Engineering Research Center of Innovative Vaccine of Beijing Vigoo Co., Ltd.
Click Here to Manage Email Alerts